Biotech Volatility | Pfizer (PFE.US) Surges Over 4% as Q2 Earnings and Profit Exceed Expectations

We have learned from our sources that on Tuesday, Pfizer (PFE.US) surged over 4%, closing at $24.52. The company released its second-quarter earnings report, with the quarter's revenue reaching $14.7 billion, exceeding expectations of $13.47 billion; earnings per share were $0.78, surpassing expectations of $0.57. The strong demand for heart disease medication Vyndaqel and anticoagulant Eliquis drove both revenue and profit above expectations.

Pfizer currently expects adjusted earnings per share to reach $2.90 to $3.10 in 2025, up from its previous guidance of $2.80 to $3.00. The midpoint of the revised guidance was raised by $0.10, exceeding market consensus expectations of $3.01. The company maintains its revenue guidance for the year at $61 billion to $64 billion.